To examine the role of immune cells in the pathogenesis of metabolic dysfunction-associated steatohepatitis (MASH) and propose a comprehensive management strategy that integrates both metabolic and immunological approaches.
Key Findings:
MASH is an immunometabolic disorder where immune dysregulation drives disease progression, necessitating a shift in therapeutic focus.
The liver's immune environment is crucial in the development and progression of MASH, highlighting the importance of immune modulation.
Current therapeutic strategies primarily focus on metabolic aspects, neglecting the role of immune modulation, which could enhance treatment efficacy.
Interpretation:
MASH should be viewed through an immunometabolic lens, recognizing the complex interactions between immune responses and metabolic dysfunction, which have significant clinical implications.
Limitations:
The review may not encompass all recent studies or emerging therapies, potentially overlooking important advancements.
The complexity of immune interactions in MASH may not be fully captured, and there may be biases in the reviewed studies.
Conclusion:
A comprehensive understanding of hepatic immune dynamics is essential for effective management of MASH, integrating both metabolic and immunological perspectives.
